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The leaves of Ficus semicordata Buch-Ham.ex Sm., locally in North India is referred to as Bhumi udumbara have been 
reported for their traditional use to cure jaundice and various liver ailments. Despite its extensive usage in northeastern 
states of India, there is a lack of scientific substantiation on the safety and pharmacotherapeutic efficacy. The present study 
was carried out to evaluate the hepatoprotective activity of F. semicordata (FS) leaves aqueous extract on HepG2 cell line to 
validate its ethnic claim in the management of liver disorders. D-galactosamine induced HepG2 cell toxicity model was used 
to evaluate its hepatoprotective activity. The cells were treated with different concentrations of aqueous extracts and 
dexamethasone as a standard. MTT assay was performed to determine the % inhibition of hepatotoxicity. The result 
indicates that the toxicity induced by D-galactosamine is reduced by FS aqueous extract group which is better when 
compared with the standard drug. This study revealed the hepatoprotective potential of F. semicordata on HepG2 
cell line. 
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Introduction 
Ficus semicordata Buch.-Ham. ex Sm., commonly 
known as drooping fig is a medium-sized evergreen 
tree, having oblong leaves with scabrid petioles. The 
tree typically lacks aerial roots. This plant with grey 
bark and pendulous branches bears pear-shaped figs. 
These figs often mature underground and hence the 
term Bhumi udumbara1,2. This plant is commonly 
found in India, Nepal, China, Bhutan and South-east 
Asian countries. It is distributed in forests ranging 
from Chenab to Myanmar3. The various parts of 
F. semicordata reported for medicinal uses are leaves,
roots, bark, figs and latex and these are advocated in
the management of liver ailments, jaundice, stomach
disorders, wound, scabies, leprosy, indigestion and
skin diseases4,5. The whole plant has been reported to
possess steroids, terpenoids, flavonoids and
glycosides5. Its leaves, in particular, possess
catechins, quercetin, quercitrin and flavonoids6. It is
also reported for anti-oxidant7, anti-bacterial activity8
and anti-diabetic activity9. Inspite of its extensive use
in liver disorders and jaundice, the validated data for
the claim is deficient. Hence, this study was planned 
to evaluate the hepatoprotective activity of 
F. semicordata leaf to validate its ethnic claim in the
management of liver disorders.
Material and Methods 
Plant collection and identification 
The plant F. semicordata, growing naturally in 
Gandhamardana hills, Paikmal, Odisha, was identified 
by local Vaidya and taxonomist. The botanical name, 
F. semicordata was confirmed by studying the
morphological characters in various floras. Sample
specimen was authenticated by Dr Harisha C R, the
head of pharmacognosy laboratory of Gujarat
Ayurved University, Jamnagar. Sample herbarium
was deposited to institute’s pharmacognosy museum
(6249/17-18) in November 2017 and also to Botanical
Survey of India (CNH/Tech.II/2018/11)10.
Sample preparation of plant extracts 
Aqueous extract of F. semicordata (FS) was 
prepared as per protocol mentioned in Ayurvedic 
Pharmacopoeia of India11. The leaves of FS were 
shade dried at room temperature. Dried leaves were 
pulverized to obtain a coarse powder. Five grams of 








100 mL of distilled water (six hours of shaking and  
18 hours stand still method) to maximally yield 
soluble compounds. Later, this was filtered through 
Whatman filter paper, and the filtrate obtained was 
lyophilized using Lyophilizer (Labconco) at -50 °C 
and 0.020 mBarr pressure for 4-6 h to yield dried 
extract powder. The dried extract obtained was  
0.7 g after lyophilization (14% yield) which was 
stored in an airtight container till further use. 
 
Animal tissue culture 
In this study, HepG2 cell line was procured from 
NCCS (National Centre of Cell Science), Pune. These 
cells were cultured and maintained in Minimum 
Essential Medium (MEM, Gibco-Invitrogen) media 
supplemented with 10% fetal bovine serum (FBS), 
Penicillin (100 U/mL) and Streptomycin (100 µg/mL) 
and incubated at 37 0C in a humidified incubator with 
5% CO2, 95% air. Cultures were regularly examined 
using an inverted microscope at 20X magnification 
and media changes were given every alternate day. 
Cells were grown till 70% confluency was achieved 
i.e.~1x106/mL in T-25 tissue culture flask and then 
were sub-culturedas per the ATCC guidelines. 
 
Cytotoxicity assay 
Cytotoxicity assay was performed using MTT- [3-
(4, 5 – dimethylthiazol–2-yl)-2,5-diphenyl tetrazolium 
bromide salt]. The cells were treated with different 
concentrations (50, 100, 150 and 200 µg/mL) of the 
plant extract and the absorbance was recorded using 
ELISA plate reader (EPOCH) at 540 nm12. 
 
In-vitro hepatoprotective activity 
Hepatotoxicity was induced in the cells using 15 
mM of D-galactosamine as per the method described 
by Brindha et al., (2015)12. The concentration of  
D-galactosamine was fixed after standardization. The 
test drug stock solution (2 mg/mL) was prepared by 
reconstituting the lyophilized FS in Milli-Q water 
during every experiment. The hepatotoxicity induced 
cells were treated with four different concentrations of 
the FS extract (FS1-50 µg/mL, FS2-100 µg/mL, FS3-
150 µg/mL and FS4-200 µg/mL). Dexamethasone at 
1.4 µM concentration was used as a standard drug 
against the D-galactosamine induced cells13. 
 
Data analysis 
Data obtained has been represented as mean±SD 
from triplicate per treatment group. The statistical 
analysis was done using ‘GraphPad Prism’statistical 




The cytotoxicity assay results are represented in 
Fig. 1 wherein HepG2 cells treated with various 
concentrations of test drug showed similar cell 
viability as in the cell blank. Thus, it is revealed that 
the test drug does not exhibit any significant toxicity 
up to 200 µg/mL. The evaluation of cytotoxicity was 




The results obtained are given in Table 1-3 and  
Fig 2. D-galactosamine control cells exhibited a 
significant reduction in cell number as compared to 
cell control, which can be reversed by the treatment 
with hepatoprotective agents. The inhibition of  
D-galactosamine induced cytotoxicity with 
dexamethasone treatment is suggestive of its ability to 
reverse the damage and protective role. When the  
D-galactosamine induced toxic cells were treated with 
various concentrations (50-200 µg/mL), it showed 
highly significant protection against toxicity as 
compared to D-galactosamine control. This protective 
effect was comparable to the control (cell blank) 
indicative of its ability to normalize the damaged 
cells. As seen in the graph the cell number has 
gradually increased as the concentration of the test 
 
Fig. 1 — HepG2 cells (Control) treated without D-galactosamine 
and test drugs (FS1-FS4) 
 
Table 1 — Application of ANOVA showing statistical  
significance at p <0.05 
ANOVA Table SS Df MS 
Treatment (between columns) 0.4922 6 0.08204 
Residual (within columns) 0.1312 21 0.006247 
Total 0.6234 27  




drug increases which is suggestive of dose-
dependent response. When the hepatotoxic cells 
were treated with 50 µg/mL, the cells showed 
inhibition similar to the standard drug 
Dexamethasone, and the test drug at 200 µg/mL 
concentration showed viable cell number which is 
closer to the control, thus we can say that the 
toxicity of D-galactosamine is inhibited at a greater 
extent. The maximum drug concentration was 
restricted to 200 µg/mL because it will not be 
feasible to prescribe the drug in human for 
achieving concentration above 200 µg/mL for 
bioavailability in the blood. This depicts  
the hepatoprotective role of FS against  
D-galactosamine induced toxicity in HepG2 cell line.  
Discussion 
This study was planned to get an insight into the 
mode of action at the cellular level using in vitro cell-
based model. Further, in the case of the 
hepatoprotective assay, D-galactosamine was chosen 
for inducing hepatotoxicity as this is a well-
established hepatotoxin which generates damage 
analogous to viral hepatitis in humans regarding 
morphologic and functional characteristics of liver. A 
single dose can cause hepatocellular necrosis and fatty 
liver14,15. The toxicity of D-galactosamine is mainly 
linked to the reduction of uridine pools that are 
associated with limited ribonucleic acid (RNA) and 
protein synthesis, thus disturbing hepatocellular 
function16. Cholestasis caused by galactosamine is 
due to its damaging effect on bile ducts thereby 
reducing bile flow of bile salts, cholic acid and 
deoxycholic acid17. It has been reported that 
Dexamethasone counteracts hepatic inflammation and 
oxidative stress in cholestatic rats18. Thus, it was used 
as the standard in the experiment which inhibits the 
D-galactosamine induced hepatotoxicity. 
The test drug showed evidence of the hepato-
protective activity in a dose-dependent manner 
ranging from 50-200 µg/mL after which the effect 
may remain at pace with the untreated cells 
irrespective of dose. The leaves of FS have been 
reported to be rich in tannins, catechins and 
flavonoids namely quercetin2. The hepatoprotective 
Table 2 — Application of Dunnett’s multiple comparison test showing statistical significance at p <0.05 in control vs test drug groups (FS1-FS4) 
Dunnett's multiple comparison test Mean Difference q Significant? P < 0.05? Summary 95% CI of diff 
Control vs Dgal 0.4080 7.300 Yes *** 0.2520 to 0.5640 
Control vs Dgal+dexa 0.2000 3.578 Yes ** 0.04400 to 0.3560 
Control vs FS1+Dgal 0.1925 3.444 Yes * 0.03650 to 0.3485 
Control vs FS2+Dgal 0.08250 1.476 No ns -0.07350 to 0.2385 
Control vs FS3+Dgal 0.05875 1.051 No ns -0.09725 to 0.2148 
Control vs FS4+Dgal 0.01575 0.2818 No ns -0.1403 to 0.1718 
***- highly significant; **-significant 
 
Table 3 — Application of Dunnett’s multiple comparison test showing statistical significance at p <0.05 in  
D-galactosamine versus test drug groups (FS1-FS4) 
Dunnett's multiple 
comparison test 
Mean difference q Significant? P <0.05? Summary 95% CI of diff 
Dgal vs Control  -0.4080 7.300 Yes *** -0.5640 to -0.2520 
Dgal vs Dgal+dexa -0.2080 3.722 Yes ** -0.3640 to -0.05200 
Dgal vs FS1+Dgal -0.2155 3.856 Yes ** -0.3715 to -0.05950 
Dgal vs FS2+Dgal -0.3255 5.824 Yes *** -0.4815 to -0.1695 
Dgal vs FS3+Dgal -0.3493 6.249 Yes *** -0.5053 to -0.1932 
Dgal vs FS4+Dgal -0.3923 7.018 Yes *** -0.5483 to -0.2362 
***- highly significant; **-significant 
 
Fig. 2 — HepG2 cells treated with D-galactosamine and test drugs
(FS1-FS4). 




effect of FS may be due to its phytoconstituent 
quercetin a flavonoid and catechin which have 
antioxidant effect thereby preventing ROS formation 
and damage to hepatocyte as observed in the 
study19,20. This hepatoprotective activity of FS leaves 
substantiates the ethnomedicinal claim in 
management of liver disorders and leaf decoction in 
combination with other plant extract is taken orally to 
get relief from jaundice21. The jaundice is described in 
Ayurveda under Kamala which is mainly due to Pittaja 
vitiation. The liver is a mulasthana (primary site) of 
Raktajavyadhi (blood disorders). In a preliminary study 
in healthy volunteers, the Rasa of dried powder of leaves 
of FS is found to be Kashaya (astringent taste), madhura 
(sweet taste)22. Kashaya rasa is reported to be 
Kledamedavishoshan (useful in dyslipidemia having 
scraping action) and hence could have a possible role in 
reducing cholestasis. Also, it is tvakprasadana 
(~enhancing  dermal health by removing toxins which 
here can be correlated to epithelium of liver) which can 
be possibly correlated to the repair of liver tissue and can 




The present study substantiates the hepato-
protective potential of aqueous extract of  
F. semicordata leaves by alleviating the in vitro  
D-galactosamine induced hepatotoxicity in HepG2 
cells. In vitro cell-based assay results observed in the 
present study must be correlated with suitable in vivo 
model and could give better insights into the role of  
F. semicordata in evaluating hepatoprotective activity 
clinically. There is a need for chemical evaluation  
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